NanoString Customers Present First Data Using the Most Comprehensive Spatial Proteomics Panel Available

Rhea-AI Summary

NanoString Technologies announces researchers sharing first insights utilizing the GeoMx Immuno-oncology Proteome Atlas at the 38th annual meeting of the Society for Immunotherapy of Cancer. The GeoMx IPA is the industry's most comprehensive spatial proteomics panel, allowing spatial profiling of over 570 relevant targets. The assay offers more than five times the content of any competing panel and has applications in biomarker discovery, drug target investigation, therapeutic response, patient stratification, and drug mechanism determination.

Leading researchers in breast and pancreatic cancer share first insights utilizing the GeoMx Immuno-oncology Proteome Atlas

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today the line-up of researchers joining NanoString at the 38^th annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held in San Diego, CA.

Dr. Aubrey Thompson of the Mayo Clinic and Amaya Pankaj, a research fellow from Dr. David Ting’s Lab at Massachusetts General Hospital, will share the first data from NanoString’s newest assay for the GeoMx® Digital Spatial Profiler (DSP). The GeoMx Immuno-oncology Proteome Atlas (IPA) is the industry’s most comprehensive spatial proteomics panel, enabling unprecedented spatial profiling of more than 570+ relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections.

Dr. Thompson will share a comparison of early-stage HER2+ tumor biopsies from patients, both responders and non-responders to neoadjuvant treatment. “The ability to interrogate the abundance and spatial distribution of 570 proteins is little short of breathtaking,” said Dr. Thompson. He added, “The initial data that we have generated using the IPA assay are very provocative, and we look forward to using these exciting new reagents to further explore the spatial biology of breast cancer.”

The GeoMx IPA assay offers researchers more than five times the content of any competing panel, providing access to unparalleled information. Its utility is applicable to the search for novel biomarkers and drug targets, investigating therapeutic response, stratifying patients, and determining drug mechanisms of action.

NanoString will host a lunchtime symposium on Friday, November 3^rd, entitled Revolutionizing Immuno-oncology with Spatial Biology. The workshop will feature a presentation by Ms. Pankaj from David Ting’s Lab on the dissection of pancreatic tumor cells by harnessing spatial multiomics using two NanoString products on the same slide, the GeoMx IPA for protein and the Whole Transcriptome Atlas for RNA. NanoString’s Chief Scientific Officer and SVP of R&D, Dr. Joseph Beechem, and Senior Director of Product Management, Vik Devgan, also will provide an overview of NanoString’s spatial biology solutions, applications and high-level product roadmap. The workshop will be held from 12:15 – 1:15 p.m. (PT) in room 16 AB.

With its partners Abcam and Visiopharm, NanoString will host an IPA happy hour from 5:00-7:00 p.m. also on November 3^rd at its conference booth, number 213. Both partners will participate in all events and be available at NanoString’s booth during the conference to provide additional information.

“NanoString is honored to offer customers the unprecedented utility and power encapsulated in the new GeoMx IPA assay. We look forward to many opportunities during SITC to discuss its transformative potential for researchers,” said Brad Gray, President and CEO of NanoString.

The GeoMx IPA is available for pre-order now and will commence shipment in November 2023.

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit www.nanostring.com.

The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231101806981/en/

Doug Farrell, NanoString

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Source: NanoString Technologies, Inc.

FAQ

Who is announcing the first insights utilizing the GeoMx Immuno-oncology Proteome Atlas?

NanoString Technologies

What is the GeoMx Immuno-oncology Proteome Atlas?

It is the industry's most comprehensive spatial proteomics panel, enabling spatial profiling of over 570 relevant targets.

What are the applications of the GeoMx IPA assay?

It can be used for biomarker discovery, drug target investigation, therapeutic response analysis, patient stratification, and drug mechanism determination.

When will the GeoMx IPA be available for shipment?

It will commence shipment in November 2023.